Partial
Mostly Aligned
Patient Risk:
Low
Summary
One of three claims aligns with the provided FDA label indication (acute attacks of HAE), while claims about manufacturing/US marketing are not supported by the provided label excerpts and cannot be verified from the supplied prescribing information.
Category Scores
Accurate Statements
Kalbitor is used to treat acute attacks of hereditary angioedema (HAE).
INDICATIONS AND USAGE: Indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Unsupported Statements
Kalbitor (ecallantide) is manufactured by Daiichi Sankyo.
Not present in the provided FDA label section/excerpts (absent from the label per audit output).
Kalbitor is marketed in the United States by Daiichi Sankyo.
Not present in the provided FDA label section/excerpts (absent from the label per audit output).
Contradictions
Important Omissions
Indication is limited to patients 12 years of age and older; the claim did not include the age threshold.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-aligned claim concerns the indicated condition; however, omission of the labeled age threshold may affect accuracy for appropriate patient selection.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Manufacturer/marketing claims are not supported by the provided label excerpts; the age restriction (≥12 years) was omitted from the indication claim.
Suggested Improvement
Restrict audit-supported statements to what is present in the provided FDA label text (e.g., include 'patients 12 years of age and older' when stating the acute HAE indication). Avoid manufacturing/marketing attributions unless supported by the label sections provided.